Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine
2. Cl 71,563
3. Cl-71,563
4. Cl71,563
5. Cloxazepine
6. Hydrochloride, Loxapine
7. Loxapine
8. Loxapine Hydrochloride
9. Loxapine Monohydrochloride
10. Loxapinsuccinate
11. Loxipine Maleate
12. Loxipine Succinate
13. Loxitane
14. Maleate, Loxipine
15. Oxilapine
16. Succinate, Loxapine
1. 27833-64-3
2. Loxapine Succinate Salt
3. Loxapac
4. Cloxazepin
5. Daxolin
6. Loxapine (succinate)
7. Loxapine, Succinate
8. Cl 71563
9. Loxapine,succinate
10. X59sg0mryu
11. Nsc-759578
12. Cl-71563
13. Cpd000058470
14. Mls000069383
15. Butanedioic Acid, Compd. With 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine (1:1)
16. Ncgc00016160-02
17. Lederle
18. Smr000058470
19. Cas-27833-64-3
20. Dsstox_cid_25227
21. Dsstox_rid_80764
22. Dsstox_gsid_45227
23. 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine Succinate (1:1)
24. Chebi:6549
25. Loxapine Succinate [usan]
26. Butanedioic Acid;8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
27. Butanedioic Acid, Compd. With 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1)
28. Ccris 1917
29. Az-004
30. Sr-01000002971
31. Einecs 248-682-0
32. Unii-x59sg0mryu
33. Loxapine Succinate [usan:usp]
34. Staccato-loxapine
35. Loxitane (tn)
36. Prestwick_304
37. Mfcd00069298
38. Lopac-l-106
39. Opera_id_1518
40. Loxapine Succinate (usp)
41. 2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine Succinate
42. Schembl41643
43. Maprotilinehydrochloride
44. Mls000758291
45. Mls001146961
46. Mls001401432
47. Mls002222201
48. Spectrum2300242
49. Loxapine Succinate Salt, Solid
50. Regid_for_cid_71399
51. Loxapine Succinate [mi]
52. Chembl1201155
53. Dtxsid3045227
54. Hms1568k06
55. Hms1922l14
56. Hms2051e05
57. Hms2093n20
58. Hms2095k06
59. Hms2232n05
60. Hms3262o21
61. Hms3374f02
62. Hms3393e05
63. Hms3652o10
64. Hms3712k06
65. Hms3885h03
66. Loxapine Succinate [vandf]
67. Pharmakon1600-02300242
68. Loxapine Succinate [mart.]
69. Loxapine Succinate [usp-rs]
70. Loxapine Succinate [who-dd]
71. Tox21_110311
72. Tox21_500720
73. Az-104
74. Ccg-39497
75. Hy-17390a
76. Nsc759578
77. S4086
78. Akos015994711
79. Tox21_110311_1
80. Cs-4285
81. Ks-1083
82. Lp00720
83. Nc00011
84. Nsc 759578
85. Loxapine Succinate [orange Book]
86. Ncgc00016160-01
87. Ncgc00016160-03
88. Ncgc00016160-04
89. Ncgc00016160-05
90. Ncgc00021145-11
91. Ncgc00094068-01
92. Ncgc00094068-02
93. Ncgc00094068-03
94. Ncgc00261405-01
95. Loxapine Succinate [usp Monograph]
96. Succinic Acid, Compd. With 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1)
97. Succinic Acid, Compound With 2-chloro-11-(4-methylpiperazin-1-yl)dibenz(b,f)(1,4)oxazepine (1:1)
98. Eu-0100720
99. Ft-0653022
100. Sw196603-4
101. Vu0239541-8
102. D00794
103. F14786
104. 833l643
105. Sr-01000002971-2
106. Sr-01000002971-6
107. Sr-01000002971-9
108. W-107092
109. Q27107236
110. 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine Succinate
111. 2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepinesuccinate
112. Loxapine Succinate, United States Pharmacopeia (usp) Reference Standard
113. (e)-2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine Succinate
Molecular Weight | 445.9 g/mol |
---|---|
Molecular Formula | C22H24ClN3O5 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 4 |
Exact Mass | 445.1404486 g/mol |
Monoisotopic Mass | 445.1404486 g/mol |
Topological Polar Surface Area | 103 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 542 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Loxapine succinate |
Drug Label | Loxapine, a dibenzoxazepine compound, represents a subclass of tricyclic antipsychotic agents, chemically distinct from the thioxanthenes, butyrophenones, and phenothiazines. Chemically, it is 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxaze... |
Active Ingredient | Loxapine succinate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 5mg base; eq 50mg base; eq 10mg base; eq 25mg base |
Market Status | Prescription |
Company | Lannett Holdings; Watson Labs; Mikah Pharma; Mylan |
2 of 2 | |
---|---|
Drug Name | Loxapine succinate |
Drug Label | Loxapine, a dibenzoxazepine compound, represents a subclass of tricyclic antipsychotic agents, chemically distinct from the thioxanthenes, butyrophenones, and phenothiazines. Chemically, it is 2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxaze... |
Active Ingredient | Loxapine succinate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 5mg base; eq 50mg base; eq 10mg base; eq 25mg base |
Market Status | Prescription |
Company | Lannett Holdings; Watson Labs; Mikah Pharma; Mylan |
Antipsychotic Agents
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. (See all compounds classified as Antipsychotic Agents.)
Dopamine Antagonists
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Loxapine Succinate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Loxapine Succinate, including repackagers and relabelers. The FDA regulates Loxapine Succinate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Loxapine Succinate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Loxapine Succinate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Loxapine Succinate supplier is an individual or a company that provides Loxapine Succinate active pharmaceutical ingredient (API) or Loxapine Succinate finished formulations upon request. The Loxapine Succinate suppliers may include Loxapine Succinate API manufacturers, exporters, distributors and traders.
click here to find a list of Loxapine Succinate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Loxapine Succinate DMF (Drug Master File) is a document detailing the whole manufacturing process of Loxapine Succinate active pharmaceutical ingredient (API) in detail. Different forms of Loxapine Succinate DMFs exist exist since differing nations have different regulations, such as Loxapine Succinate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Loxapine Succinate DMF submitted to regulatory agencies in the US is known as a USDMF. Loxapine Succinate USDMF includes data on Loxapine Succinate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Loxapine Succinate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Loxapine Succinate suppliers with USDMF on PharmaCompass.
A Loxapine Succinate written confirmation (Loxapine Succinate WC) is an official document issued by a regulatory agency to a Loxapine Succinate manufacturer, verifying that the manufacturing facility of a Loxapine Succinate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Loxapine Succinate APIs or Loxapine Succinate finished pharmaceutical products to another nation, regulatory agencies frequently require a Loxapine Succinate WC (written confirmation) as part of the regulatory process.
click here to find a list of Loxapine Succinate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Loxapine Succinate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Loxapine Succinate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Loxapine Succinate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Loxapine Succinate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Loxapine Succinate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Loxapine Succinate suppliers with NDC on PharmaCompass.
Loxapine Succinate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Loxapine Succinate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Loxapine Succinate GMP manufacturer or Loxapine Succinate GMP API supplier for your needs.
A Loxapine Succinate CoA (Certificate of Analysis) is a formal document that attests to Loxapine Succinate's compliance with Loxapine Succinate specifications and serves as a tool for batch-level quality control.
Loxapine Succinate CoA mostly includes findings from lab analyses of a specific batch. For each Loxapine Succinate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Loxapine Succinate may be tested according to a variety of international standards, such as European Pharmacopoeia (Loxapine Succinate EP), Loxapine Succinate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Loxapine Succinate USP).
LOOKING FOR A SUPPLIER?